GRCE net incomeQ1 2027-$15.79M
GRCE net income was -$15.79M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$3.36M a year earlier. For the full fiscal 2026 it was -$7.79M, compared with -$9.57M in fiscal 2025.
Grace Therapeutics Inc. (GRCE) financials
For the twelve months ended Jun 30, 2026, Grace Therapeutics Inc. reported -$20.22M of net income.
- Net income, TTM
- -$20.22M
- EPS, diluted, TTM
- -$1.17
- Cash
- $13.76M
- Market cap
- $38.9M
FY2021FY2022
FY2019FY2026
GRCE revenue and earnings growth
GRCE EPSQ1 2027-$0.91
GRCE diluted EPS was -$0.91 in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$0.21 a year earlier. For the full fiscal 2026 it was -$0.47, compared with -$0.79 in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | $100.00M | $196.0K | - | - |
| Cost of revenue | - | - | - | - | $0 | $76.0K | - | - |
| Gross profit | - | - | - | - | $100.00M | $120.0K | - | - |
| Research and development | $2.40M | $9.51M | $4.68M | $9.97M | $5.56M | $4.17M | $15.97M | $29.37M |
| Selling, general and admin | $8.67M | $7.17M | $6.68M | $7.61M | $9.26M | $5.52M | $5.80M | $4.54M |
| Operating income | -$11.08M | -$16.68M | -$12.85M | -$52.16M | -$15.59M | -$16.42M | -$24.44M | -$34.41M |
| Pre-tax income | -$9.49M | -$12.77M | -$14.69M | -$51.97M | -$10.47M | -$19.68M | -$25.51M | -$39.37M |
| Income tax | -$1.70M | -$3.20M | -$1.83M | -$9.54M | -$648.0K | $0 | $0 | $0 |
| Net income | -$7.79M | -$9.57M | -$12.85M | -$42.43M | -$9.82M | -$19.68M | -$25.51M | -$39.37M |
| EPS, basic | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | -$7.98 | -$14.40 | -$35.04 |
| EPS, diluted | -$0.47 | -$0.79 | -$1.35 | -$5.71 | -$1.62 | -$7.98 | -$14.40 | -$35.04 |
| Diluted shares | 16.5M | 12.1M | 9.5M | 7.4M | 6.1M | 2.5M | 1.8M | 1.1M |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $16.98M | $22.13M | $23.00M | $27.88M | $30.34M | $50.94M | $14.24M | $16.87M |
| Short-term investments | - | - | $0 | $15.0K | $13.32M | $9.79M | - | $8.89M |
| Receivables | - | - | $722.0K | $802.0K | $548.0K | $530.0K | $546.0K | $1.19M |
| Current assets | $17.38M | $22.71M | $24.01M | $29.29M | $45.28M | $62.37M | $18.46M | $27.97M |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $12.96M | - | - | - |
| Total assets | $66.65M | $71.99M | $73.30M | $79.12M | $128.62M | $62.46M | $22.85M | $36.90M |
| Current liabilities | $2.15M | $1.93M | $1.68M | $3.41M | $3.26M | $1.58M | $7.39M | $13.67M |
| Total liabilities | $2.76M | $5.38M | $11.56M | $11.17M | $20.35M | $6.80M | $9.86M | $25.85M |
| Shareholders' equity | $63.90M | $66.61M | $61.74M | $67.95M | $108.27M | $55.66M | $12.99M | $11.04M |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$8.87M | -$14.90M | -$12.33M | -$15.91M | -$17.23M | -$14.32M | -$22.95M | - |
| Investing cash flow | $0 | $0 | $104.0K | $13.15M | -$3.52M | -$9.86M | $8.14M | - |
| Financing cash flow | $3.71M | $14.03M | $7.36M | $304.0K | $0 | $59.49M | $13.18M | - |
| Stock-based compensation | $798.0K | $730.0K | $913.0K | $1.81M | $1.34M | $1.17M | $1.95M | - |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | 50920.4% | - | - | - |
| Gross margin | - | - | - | - | 100.0% | 61.2% | - | - |
| Operating margin | - | - | - | - | -15.6% | -8377.0% | - | - |
| Net margin | - | - | - | - | -9.8% | -10039.8% | - | - |
| Return on equity | -12.2% | -14.4% | -20.8% | -62.4% | -9.1% | -35.4% | -196.3% | -356.4% |
| Return on assets | -11.7% | -13.3% | -17.5% | -53.6% | -7.6% | -31.5% | -111.6% | -106.7% |
| Current ratio | 8.10 | 11.77 | 14.26 | 8.59 | 13.89 | 39.50 | 2.50 | 2.05 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $697.0K | $420.0K | $462.0K | $568.0K | $955.0K | $1.63M | $2.19M | $2.98M | $2.71M | $1.69M | $1.44M | $460.0K |
| Selling, general and admin | $1.69M | $2.59M | $1.99M | $1.96M | $2.13M | $1.55M | $1.51M | $1.85M | $2.25M | $1.58M | $1.60M | $1.63M |
| Operating income | -$15.92M | -$3.01M | -$2.45M | -$2.53M | -$3.09M | -$3.18M | -$3.70M | -$4.83M | -$4.96M | -$3.26M | -$3.04M | -$2.09M |
| Pre-tax income | -$15.79M | -$2.88M | -$2.31M | -$938.0K | -$3.36M | -$382.0K | -$4.76M | -$4.28M | -$3.34M | -$4.05M | -$2.60M | -$3.72M |
| Income tax | $0 | -$1.70M | $0 | $0 | $0 | -$1.02M | -$605.0K | -$852.0K | -$724.0K | -$889.0K | -$208.0K | -$446.0K |
| Net income | -$15.79M | -$1.18M | -$2.31M | -$938.0K | -$3.36M | $636.0K | -$4.16M | -$3.43M | -$2.62M | -$3.17M | -$2.39M | -$3.27M |
| EPS, basic | -$0.91 | -$0.06 | -$0.14 | -$0.06 | -$0.21 | $0.11 | -$0.36 | -$0.30 | -$0.24 | - | -$0.21 | -$0.43 |
| EPS, diluted | -$0.91 | -$0.06 | -$0.14 | -$0.06 | -$0.21 | $0.11 | -$0.36 | -$0.30 | -$0.24 | - | -$0.21 | -$0.43 |
| Diluted shares | 17.3M | - | 16.9M | 15.9M | 15.9M | - | 11.5M | 11.5M | 10.9M | - | 11.5M | 7.6M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.76M | $16.98M | $18.67M | $16.86M | $20.00M | $22.13M | $11.05M | $15.15M | $19.39M | $23.00M | $18.55M | $26.99M |
| Short-term investments | - | - | - | - | - | - | - | $15.0K | $15.0K | $0 | $6.57M | $15.0K |
| Receivables | - | - | - | - | - | - | - | - | $398.0K | $722.0K | $959.0K | $837.0K |
| Current assets | $14.33M | $17.38M | $19.21M | $17.30M | $20.52M | $22.71M | $11.94M | $16.06M | $20.43M | $24.01M | $26.88M | $28.89M |
| Goodwill | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M | $8.14M |
| Total assets | $50.07M | $66.65M | $68.49M | $66.58M | $69.81M | $71.99M | $61.22M | $65.35M | $69.72M | $73.30M | $76.19M | $78.21M |
| Current liabilities | $1.25M | $2.15M | $1.28M | $1.25M | $2.31M | $1.93M | $1.97M | $2.67M | $2.60M | $1.68M | $1.77M | $1.40M |
| Total liabilities | $1.86M | $2.76M | $3.60M | $3.76M | $6.25M | $5.38M | $9.09M | $9.21M | $10.35M | $11.56M | $11.51M | $11.46M |
| Shareholders' equity | $48.21M | $63.90M | $64.89M | $62.82M | $63.55M | $66.61M | $52.14M | $56.13M | $59.36M | $61.74M | $64.68M | $66.75M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$3.22M | -$1.70M | -$2.23M | -$3.14M | -$1.80M | -$2.95M | -$4.12M | -$4.24M | -$3.60M | -$2.09M | -$1.89M | -$2.11M |
| Investing cash flow | - | $0 | $0 | $0 | $0 | $0 | $15.0K | $0 | -$15.0K | $6.55M | -$6.55M | $110.0K |
| Financing cash flow | $0 | $0 | $4.04M | $0 | -$327.0K | $14.03M | $0 | $0 | $0 | $0 | $0 | $7.36M |
| Stock-based compensation | $105.0K | $182.0K | $108.0K | $206.0K | $302.0K | $130.0K | $160.0K | $202.0K | $238.0K | $229.0K | $326.0K | $280.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 11.47 | 8.10 | 14.96 | 13.89 | 8.87 | 11.77 | 6.06 | 6.01 | 7.86 | 14.26 | 15.19 | 20.68 |
Source: XBRL data Grace Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-8, first reported Nov 10, 2021; 1-for-6, first reported Aug 11, 2023.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
GRCE peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| GRCE | - | - | -$20.22M | - | $38.9M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.27T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $664.95B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $514.92B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $361.71B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $310.17B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.10B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $190.39B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $178.51B |
GRCE FAQ
5 questionsIs GRCE profitable?
No. Grace Therapeutics Inc. reported a net loss of $20.22M for the twelve months ended Jun 30, 2026.How much cash and debt does GRCE have?
Grace Therapeutics Inc. reported $13.76M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is GRCE earnings per share?
Diluted earnings per share were -$1.17 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did GRCE last report financial results?
The latest statements here come from Grace Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this GRCE financial data come from?
Quantisnow builds these statements from the structured XBRL data Grace Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.